Fairfield Financial Advisors, LTD Crispr Therapeutics Ag Transaction History

Fairfield Financial Advisors, LTD

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Nov 04, 2024	BUY	$41.0 - $56.12 $2,501 - $3,423	61 New	61 $2.69 Million
Q3 2022 Oct 07, 2024	BUY	$61.1 - $83.78 $7,148 - $9,802	117 New	117 $7.65 Million
Q2 2022 Oct 07, 2024	BUY	$43.23 - $73.83 $5,057 - $8,638	117 New	117 $7.11 Million
Q1 2022 Oct 07, 2024	BUY	$53.19 - $79.24 $6,223 - $9,271	117 New	117 $7.34 Million

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.23B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Fairfield Financial Advisors, LTD, based on Form 13F filings with the SEC.

Stay updated on Fairfield Financial Advisors, LTD with notifications on news.